

IRLAB's mesdopetam featured on cover of top-tier publication *JPET*

IRLAB announced today that IRLAB's candidate drug mesdopetam (IRL790) is featured on the cover of the July 01, 2020, issue of the highly ranked scientific journal *JPET*. The cover illustrates how mesdopetam binds to the dopamine D3 receptor. The scientific paper further describes the compounds beneficial system level effects in the brain. Mesdopetam is in development for the treatment of motor and psychiatric complications in Parkinson's disease.

"We are proud that IRLAB by means of our systems biology discovery strategy, ISP, has discovered and developed a candidate drug that is now featured on the cover of the prestigious scientific journal *JPET*", said Nicholas Waters, CEO at IRLAB. "It is rewarding that IRLAB receives such an acknowledgement."

JPET, The Journal of Pharmacology and Experimental Therapeutics, is a highly ranked international research journal in the field of pharmacology. The journal is published by The American Society for Pharmacology and Experimental Therapeutics.

In an earlier press release, it was announced that the paper was published online as part of *JPET Fast Forward*, which contains papers in manuscript form that have been accepted and published in *JPET*.

Publication: Waters, S. *et al.* Preclinical pharmacology of [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine (IRL790), a novel dopamine transmission modulator for the treatment of motor and psychiatric complications in Parkinson's disease. *Journal of Pharmacology and Experimental Therapeutics*, DOI: <https://doi.org/10.1124/jpet.119.264226>

For more information

Nicholas Waters, CEO
Tel: +46 730 75 77 01
E-mail: nicholas.waters@irlab.se

About IRLAB

IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson's disease. The company's most advanced candidates, mesdopetam (IRL790) and IRL752, both of which completed Phase IIa-studies, intends to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through the proprietary research platform, ISP (The Integrative Screening Process), IRLAB discovers and develops drug candidates for central nervous system (CNS) related disorders where large and growing medical need exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. IRLAB's Certified Adviser on Nasdaq First North Premier Growth Market is FNCA Sweden AB, info@fnca.se, +46 (0)8528 00 399. More information on www.irlab.se.